Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD

Environmental Health Perspectives

Volumn 114, Issue 9, 2006, Pages 1394-1400

  Emond, Claude ^a,b,c   Birnbaum, Linda S ^b   DeVito, Michael J ^b  

^a NATIONAL RESEARCH COUNCIL   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adipose tissue; AhR; Aryl hydrocarbon receptor; Dioxin; Modeling; PBPK; Pharmacokinetics; TCDD

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; CYTOCHROME P450 1A2;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CONTROLLED STUDY; DOSE RESPONSE; ELIMINATION REACTION; ENZYME INDUCTION; HALF LIFE TIME; LIPOPHILICITY; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; TOXICOKINETICS;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; ENZYME INDUCTION; FEMALE; HALF-LIFE; MALE; RATS; RATS, SPRAGUE-DAWLEY; TETRACHLORODIBENZODIOXIN; TISSUE DISTRIBUTION;

EID: 33748143400     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.8805     Document Type: Article

References (47)

1. Abraham K, Geusau A, Tosun Y, Helge H, Bauer S, Brockmoller J. 2002. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Clin Pharmacol Ther 72:163-174.
2. Abraham K, Krowke R, Neubert D. 1988. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1: Dose-dependent tissue distribution and induction of hepatic ethoxyresorufin O-deethylase in rats following a single injection. Arch Toxicol 62(5):359-368.
3. 14C]tetrachlorodibenzo-p-dioxin in rats. Food Cosmet Toxicol 13:501-505.
4. Andersen ME, Birnbaum LS, Barton HA, Eklund C. 1997. Regional hepatic CTP1A1 and CYP1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin evaluated with a multicompartment geometric model of hepatic zonation. Toxicol Appl Pharmacol 144:145-155.
5. Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Neubert D, et al. 1993. Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13:25-36.
6. Anzenbacher P, Anzenbacherova E. 2001. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 58:737-747.
7. Aylward LL, Brunet RC, Carrier G, Hays SM, Cushing CA, Needham LL, et al. 2005. Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort. J Expo Anal Environ Epidemiol 15:51-65.
8. Aylward LL, Hays SM, Karch NJ, Paustenbach DJ. 1990. Relative suceptibility of animals and humans to the cancer hazard posed by 2,3,7,8-tetrachlorodibenzo-p-dioxin using internal measures. Environ Sci Technol 30:3534-3543.
9. Carrier G, Brunet RC, Brodeur J. 1995a. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofuranes in mammalians, including humans. II: Kinetics of absorption and disposition of PCDDs/ PCDFs. Toxicol Appl Pharmacol 131:267-276.
10. Carrier G, Brunet RC, Brodeur J. 1995b. Modeling of the toxicokinetics of polychlorinated dibenzo-p-dioxins and dibenzofurans in mammalians, including humans. Toxicol Appl Pharmacol 131:253-266.
11. Cheng PY, Morgan ET. 2001. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165-183.
12. Crump KS, Canady R, Kogevinas M. 2003. Meta-analysis of dioxin cancer dose response for three occupational cohorts. Environ Health Perspect 111:681-687.
13. DeVito MJ, Birnbaum LS. 1995. Dioxins: model chemicals for assessing receptor-mediated toxicity. Toxicology 102:115-123.
14. Diliberto JJ, Burgin DE, Birnbaum LS. 1999. Effects of CYP1A2 on disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,4,7,8-pentachlorodibenzofuran, and 2,2′,4,4′,5,5′-hexachlorobiphenyl in CYP1A2 knockout and parental (C57BL/6N and 129/Sv) strains of mice. Toxicol Appl Pharmacol 159:52-64.
15. Diliberto JJ, DeVito MJ, Ross DG, Birnbaum LS. 2001 Subchronic exposure of [3H]- 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female B6C3F1 mice: relationship of steady-state levels to disposition and metabolism. Toxicol Sci 61(2):241-255.
16. Emond C, Birnbaum LS, DeVito M 2004. Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol Sci 80:115-133.
17. Emond C, Michalek JE, Birnbaum LS, Devito MJ. 2005. Comparison of the use of a physiologically based pharmacokinetic model and a classical pharmacokinetic model for dioxin exposure assessments. Environ Health Perspect 113:1666-1668.
18. Flesch-Janys D, Becher H, Gurn P, Jung D, Konietzko J, Manz A, et al. 1996. Elimination of polychlorinated dibenzo-p-dioxins and dibenzofurans in occupationally exposed persons. J Toxicol Environ Health 47:363-378.
19. Hakk H, Diliberto JJ. 2002 Comparison of overall metabolism of 2,3,7,8-TCDD in CYP1A2 (-/-) knockout and C57BL/6N parental strains on mice. Organohalogen Compounds 55:461-464.
20. Kedderis LB, Diliberto JJ, Linko P, Goldstein JA, Birnbaum LS. 1991 Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8,-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochrome CYP1A1 and CYP1A2. Toxicol Appl Pharmacol 111:163-172.
21. Kohn MC, Sewall CH, Lucier GW, Portier CJ. 1996. A mechanistic model of effects of dioxin on thyroid hormones in the rat Toxicol Appl Pharmacol 136:29-48.
22. Lakshmanan MR, Campbell BS, Chirtel SJ, Ekarohita N, Ezekiel M. 1986. Studies on the mechanism of absorption and distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. J Pharmacol Exp Ther 239:673-677.
23. Maruyama W, Yoshida K, Tanaka T, Nakanishi J. 2002. Possible range of dioxin concentration in human tissues: simulation with a physiologically based model. J Toxicol Environ Health A 65:2053-2073.
24. Michalek JE, Pirkle JL, Needham LL, Patterson DG, Caudill SP, Tripathi RC, et al. 2002. Pharmacokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Seveso adults and veterans of operation Ranch Hand. J Expo Anal Environ Epidemiol 12:44-53.
25. Michalek JE, Tripathi RC. 1999. Pharmacokinetics of TCDD in veterans of Operation Ranch Hand: 15-year follow-up. J Toxicol Environ Health A 57:369-378.
26. Moser GA, McLachlan MS. 2002. Partitioning of polychlorinated biphenyls and hexachlorobenzene into human faeces. Chemosphere 46:449-457.
27. Olson JR, McGarrigle BP, Gigliotti PJ, Kumar S, McReynolds JH. 1995. Hepatic uptake and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzofuran. Fundam Appl Toxicol 22:631-640.
28. Pinsky PF, Lorber MN. 1998. A model to evaluate past exposure to 2,3,7,8-TCDD. J Expo Anal Environ Epidemiol 8:187-206.
29. Piper WN, Rose JQ, Gehring PJ. 1973. Excretion and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Environ Health Perspect 5:241-244.
30. 14C-TCDD in a TCCD-suceptible and a TCDD-resistant rat strain. Pharmacol Toxicol 66:93-100.
31. Poiger H, Schlatter C. 1985. Influence of phenobarbital and TCDD on the hepatic metabolism of TCDD in the dog. Experientia 41:376-378.
32. Rose JQ, Ramsey JC, Wentzler TH, Hummel RA, Gehring PJ. 1976. The fate of 2,3,7,8-tetrachlorodibenzo-p-dioxin following single and repeated oral doses to the rat. Toxicol Appl Pharmacol 36:209-226.
33. Salvan A, Thomaseth K, Bortot P, Sartori N. 2001. Use of a toxico-kinetic model in the analysis of cancer mortality in relation to the estimated absorbed dose of dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD). Sci Total Environ 274:21-35.
34. Santostefano MJ, Ross DG, Savas U, Jefcoate CR, Birnbaum LS. 1997. Differential time-course and dose-response relationships of TCDD-induced CYP1B1, CYP1A1, and CYP1A2 proteins in rats. Biochem Biophys Res Commun 233(1):20-24.
35. Santostefano MJ, Wang F, Richardson VM, Ross DG, Devito MJ, Birnbaum LS. 1998. A pharmacodynamic analysis of TCDD-induced cytochrome P450 gene expression in multiple tissues: dose- and time-dependent effects. Toxicol Appl Pharmacol 151:294-310.
36. Shinkyo R, Sakaki T, Ohta M, Inouye K. 2003. Metabolic pathways of dioxin by CYP1A1: species difference between rat and human CYP1A subfamily in the metabolism of dioxins. Arch Biochem Biophys 409:180-187.
37. Staskal DF, Diliberto JJ, Devito MJ, Birnbaum LS. 2005. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals. Toxicol Sci 2005 84:225-231.
38. Steenland K, Deddens J, Piacitelli L. 2001. Risk Assessment for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on an epidemiologic study. Am J Epidemiol 154:451-458.
39. Steiner EC, Rey TD, McCroskey PS. 1990. Reference Guide for Simusolv. Midland, MI:Dow Chemical Co
40. Tai HL, McReynolds JH, Goldstein JA, Eugster HP, Sengstag C, Alworth WL, et al. 1993. Cytochrome P4501A1 mediates the metabolism of 2,3,7,8-tetrachlorodibenzofuran in the rat and human. Toxicol Appl Pharmacol 123:34-42.
41. van der Molen GW, Kooijman SA, Michalek JE, Slob W. 1998. The estimation of elimination rates of persistent compounds: a re-analysis of 2,3,7,8-tetrachloradibenzo-p-dioxin levels in Vietnam veterans. Chemosphere 37:1833-1844.
42. van der Molen GW, Kooijman BA, Wittsiepe J, Schrey P, Flesch-Janys D, Slob W. 2000. Estimation of dioxin and furan elimination rates with a pharmacokinetic model. J Expo Anal Environ Epidemiol 10:579-585.
43. Viluksela M, Duong TV, Stahl BU, Li X, Tuomisto J, Rozman KK. 1996. Toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in two substrains of male Long-Evans rats after intravenous injection. Fundam Appl Toxicol 31:184-191.
44. Walker NJ, Portier CJ, Lax SF, Crofts FG, Li Y, Lucier GW, et al 1999. Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 154:279-286.
45. Wang X, Santostefano MJ, Devito MJ, Birnbaum LS. 2000 Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicol Sci 56:49-60.
46. Wang X, Santostefano MJ, Evans MV, Richardson VM, Diliberto JJ, Birnbaum LS. 1997. Determination of parameters responsible for pharmacokinetic behavior of TCDD in female Sprague-Dawley rats. Toxicol Appl Pharmacol 147:151-168.
47. Weber LW, Ernst SW, Stahl, BU, Rozman, K 1993. Tissue distribution and toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats after intravenous injection. Fundam Appl Toxicol 21:523-534.